Prevalence of perennial severe allergic asthma in Italy and effectiveness of omalizumab in its management: PROXIMA – an observational, 2 phase, patient reported outcomes study

Clinical and Molecular Allergy

Laura Rigoni¹  Raffaele Marino¹  Marta Bartezaghi¹  Giorgio Walter Canonica² 

[1] Novartis Farma SpA, Largo U. Boccioni 1, Origgio (VA) 21040, Italy;DIMI, IRCCS AOU San Martino, University of Genoa, Genoa, Italy

关键词: Asthma control;    Perennial;    Severe allergic asthma;    IgE;    Omalizumab;   

Others  :  1220055
DOI  :  10.1186/s12948-015-0019-7

 received in 2015-03-03, accepted in 2015-04-08,  发布年份 2015

【 摘 要 】

Background

We designed the PROXIMA study (Patient-Reported Outcomes and Xolair ^®In the Management of Asthma) to determine the proportion of patients with severe asthma sensitive to perennial allergens, and to evaluate asthma control and treatment adherence up to 12 months in patients treated with omalizumab in Italian population. In addition, an ancillary study was designed to explore protein biomarkers and characterize them in relation to severe allergic asthma and treatment effects by proteomic approach.

Methods

PROXIMA is an observational, multicenter, cross-sectional and prospective cohort study conducted at 25 centers in Italy, in outpatient settings. The study consists of two phases: 1) a cross-sectional phase plans to enroll 600 patients with severe allergic asthma, in step 4 therapy as per GINA guidelines, aged ≥18 years, needing a step up in therapy, and 2) a longitudinal phase on patients who will start omalizumab add-on therapy per clinician’s judgment at baseline visit (approximately 180–240 patients). The primary variable of the cross-sectional phase is the proportion of patients with severe asthma presenting with perennial form of allergy (skin prick test or in vitro test). The primary variable of longitudinal phase is proportion of patients who achieve disease control (assessed by Asthma Control Questionnaire [ACQ]) with omalizumab at 6 months, and maintain it at 12 months. Secondary variables are patient compliance to omalizumab, patient-reported perception of cognitive and emotional impact of the illness, assessed by Brief Illness Perception Questionnaire (Brief IPQ) and the health related quality of life evaluated by the EuroQoL 5D-3 L (EQ-5D-3 L). Safety endpoints will be recorded during the course of the study. Patients participating in the longitudinal phase will be enrolled for ancillary study if they provide additional informed consent. Protein species in complex mixtures will be identified using innovative MudPIT (Multidimensional Protein Identification Technology) method.

Conclusions

The results of this observational study will provide estimate of patient population allergic to perennial allergens in Italy and information on patient-reported outcomes with omalizumab therapy in a real-world setting. The exploratory proteomic analysis on asthma biomarkers could eventually provide new data to identify responder patients to anti IgE therapy.

【 授权许可】

   
2015 Canonica et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Mukherjee AB, Zhang Z. Allergic asthma: influence of genetic and environmental factor. J Biol Chem. 2011; 286(38):32883-9.
• [2]Shifren A, Witt C, Christie C, Castro M: Mechanisms of Remodeling in Asthmatic Airways. J Allergy. Volume 2012 (2012). http://dx. doi.org/10.1155/2012/316049 webcite
• [3]The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Resp J. 2003; 22(3):470-7.
• [4]McKeage K. Omalizumab: a review of its Use in patients with severe persistent allergic asthma. Drugs. 2013; 73:1197-212.
• [5]de Marco R, Cappa V, Accordini S, Rava M, Antonicelli L, Bortolami O et al.. Trends in the prevalence of asthma and allergic rhinitis in Italy between 1991 and 2010. Eur Respir J. 2012; 39:883-92.
• [6]Price D. The use of omalizumab in asthma. Prim Care Respir J. 2008; 17(2):62-72.
• [7]D’Amato G, Stanziola A, Sanduzzi A, Liccardi G, Salzillo A, Vitale C et al.. Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review. Multidisciplinary Respir Med. 2014; 9:23. BioMed Central Full Text
• [8]Holgate ST. Stratified approaches to the treatment of asthma. Br J Clin Pharmacol. 2012; 76:277-91.
• [9]Definition of Allergens 2013. Is there a need for Seasonal & Perennial? Available at URL: http://www.worldallergy.org/UserFiles/file/GWCMANIFESTOALLERGENSCHICAGO_FullPage.pdf, accessed on 17 Dec, 2014
• [10]Schroeder JT, Bieneman AP, Chichester KL, Hamilton RG, Xiao H, Saini SS et al.. Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization. J Allergy Clin Immunol. 2010; 125:896-901.
• [11]Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. Available at URL: http://www.ginasthma.org, accessed on Oct 27, 2014
• [12]European Medicines Agency. Xolair powder and solvent for solution for injection: summary of product characteristics; 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf (Accessed 23 Sep 2014).
• [13]Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiology and drug safety 2008; 17: 200–208. (available at URL: http://www.pharmacoepi.org/pub/1c2a23af-2354-d714-516a-7175549e3a88, accessed on 26 Sep, 2014).
• [14]von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE initiative: strengthening the reporting of observational studies in epidemiology. J Clin Epidemiol. 2008; 61(4):344-9.
• [15]AIFA Guideline for the classification and management of observational studies on drugs (Determination March 20, 2008). Available at URL: http://www.agenziafarmaco.com/en, accessed on January 12, 2015.
• [16]Juniper EF, Bousquet J, Abetz L, Bateman ED. Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the asthma control questionnaire. Respir Med. 2006; 100:616-21.
• [17]Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J of Psychosom Res. 2006; 60:631-7.
• [18]“EuroQol: a new facility for the measurement of health-related quality of life”. Health Policy. 1990; 16:199-208.
• [19]Brazier J, Jones N, Kind P. Testing the validity of the euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res. 1993; 2:169-80.
• [20]Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW et al.. An official american thoracic society/european respiratory society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009; 1(180):59-99.
• [21]Pelaia G, Gallelli L, Romeo P, Renda T, Busceti MT, Proietto A et al.. Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma. Int J Clin Pharmacol Ther. 2011; 49(12):713-21.
• [22]Vennera Mdel C, Pérez De Llano L, Bardagí S, Ausin P, Sanjuas C, González H et al.. Spanish registry: omalizumab therapy in severe asthma: experience from the spanish registry--some new approache. J Asthma. 2012; 49:416-22.
• [23]Holgate ST. Asthma: a simple concept but in reality a complex disease. Eur J Clin Invest. 2011; 41:1339-52.
• [24]Rossi R, De Palma A, Benazzi L, Riccio AM, Canonica GW, Mauri P. Biomarker discovery in asthma and COPD by proteomic approaches. Proteomics Clin Appl. 2014; 8:901-15.
• [25]Mauri P, Riccio AM, Rossi R, Di Silvestre D, Benazzi L, De Ferrari L et al.. Proteomics of bronchial biopsies: Galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. Immunol Lett. 2014; 162:2-10.
• [26]Schirmer EC, Yates JR, Gerace L. MudPIT: a powerful proteomics tool for discovery. Discov Med. 2003; 3(18):38-9.
• [27]Link AJ, Eng J, Schieltz DM, Carmack E, Mize GJ, Morris DR et al.. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol. 1999; 17:676-82.